AB-Biotics, S.A.

Equities

ABB

ES0109659013

Biotechnology & Medical Research

End-of-day quote BME Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-.--%

2022	AB-Biotics, S.A. acquired Alifarm S.A. for EUR 3.5 million.	CI
2019	Kaneka Europe Holding Company N.V. completed the acquisition of 18.21% stake in AB-Biotics, S.A.	CI

Kaneka Corporation signed an agreement to acquire 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis.

March 27, 2018

Kaneka Corporation (TSE:4118) signed an agreement to acquire 26.87% stake in AB-Biotics, S.A. (BME:ABB) from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis on March 28, 2018. Post transaction, founding partners Miquel Ángel Bonachera and Sergi Audivert will become shareholders with a joint stake of 20.22% while Chairman Luís Sánchez-Lafuente will be shareholder with 10.10%. Andrea Carreri, Giulia Cerutti and Gianluca de Cristofaro of Lega Colucci Morri & Associati and Gómez-Acebo & Pombo Abogados, S.L.P. acted as legal advisors to Kaneka Corporation.

Latest news about AB-Biotics, S.A.

AB-Biotics, S.A. acquired Alifarm S.A. for EUR 3.5 million.	22-05-31	CI
Kaneka Europe Holding Company N.V. completed the acquisition of 18.21% stake in AB-Biotics, S.A.	19-11-06	CI
Kaneka Europe Holding Company N.V. made an offer to acquire remaining 33.67% stake in AB-Biotics, S.A. for €21.2 million.	19-09-02	CI
Kaneka Corporation has completed the voluntary offer to acquire an additional 26.57% stake in AB-Biotics, S.A. for €16.7 million.	19-08-15	CI
Kaneka Corporation made a voluntary public offer to acquire the remaining 60.24% stake in AB-Biotics, S.A. for €37.9 million.	19-07-09	CI
Ab-Biotics Sa Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-21	CI
Kaneka Corporation Concludes License Agreement with AB-Biotics for Production and Sales of its Probiotics Products	18-05-10	CI
Kaneka Corporation completed the acquisition of 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis.	18-04-04	CI
Kaneka Americas Holding Inc. enters into Licensing Agreement with AB-Biotics, S.A	18-04-02	CI
Kaneka Corporation signed an agreement to acquire 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis.	18-03-27	CI
Corporacion Ivamosa and Gestion Y Administracion Mobiliaria, S.A. acquired 10% stake in AB-Biotics, S.A..	18-03-15	CI
Frutarom Industries Ltd. acquired AB-Fortis from AB-Biotics, S.A..	17-11-07	CI
AB-Biotics SA announced a financing transaction	16-10-24	CI
AB-Biotics Agrees Distribution Deal with Abbott for I3.1 Probiotic in Spain	14-12-23	CI
DuPont Nutrition & Health and AB-Biotics Announce Agreement on Probiotic for Cardiovascular Health	14-06-01	CI
AB-Biotics Provides Earnings Guidance for the Full Year of 2013	14-02-19	CI
AB-Biotics SA sold Quantum Experimental S.L.	13-10-08	CI
AB-Biotics and Scienta Farma Sign Distribution Agreement to Market Genetic Test Neurofarmagen in Mexico	13-10-04	CI
AB-Biotics SA announced that it expects to receive €1.08 million in funding.	13-08-07	CI

Chart AB-Biotics, S.A.

Duration

Period

More charts

Company Profile

AB-Biotics SA, also known as AB Biotics, is a Spain-based company engaged in the biotechnology industry business sector. It is dedicated to the research and development (R&D) of functional ingredients, drugs and tools for genetic analysis, as well as the nutraceutical and pharmaceutical industries. The Companyâs pipeline includes a range of supplements designed to improve health, from products that can lower the risk of cardiovascular disease to those that can help in the management of diabetes. It covers the development spectrum from marketed product, to proof-of-concept, and includes products that have been licensed to global food and pharmaceutical companies. The Company also provides outsourced R&D solutions to pharmaceutical companies, as well as functional food industry related companies. The Company offers different products, such as AB-Life, LipiGO, AB-Dentalac and AB-Colic, among others.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
AB-BIOTICS, S.A.	-.--%	69.57M
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	383M

Bio Diagnostics & Testing